Post hoc analysis of web-based survey (ref. UMIN000048497) on emotional blunting in Japanese patients with Major Depressive Disorder

Post hoc analysis of web-based survey (ref. UMIN000048497) on emotional blunting in Japanese patients with Major Depressive Disorder - Post hoc analysis of web-based survey (ref. UMIN000048497) on emotional blunting in Japanese patients with Major Depressive Disorder

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000051822

Enrollment

3376

Registered

2023-08-07

Start date

2022-07-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major depressive disorder (MDD)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The following subjects are eligible for the survey if they meet all of the following criteria: (1) Aged between 18 and 59 years old (regardless of gender) (2) Those who have been diagnosed with MDD. (3) Those who have been taking antidepressant medication for at least three months. (4) Those who have been visiting a hospital for more than three months. (5) Those who can use the Internet with a personal computer, smartphone, or tablet. (6) Those who can give consent online based on their own free will after understanding the explanation in Japanese.

Exclusion criteria

Exclusion criteria: The preliminary web-based questionnaire ask whether any of the following conditions are met, and those who meet the conditions are not eligible for the survey. (1) Those who have been diagnosed with bipolar disorder. (2) Those not currently taking antidepressants

Design outcomes

Primary

Measure	Time frame
Correlation of ODQ/ODQ sub-domain (General reduction (GR), Positive reduction (PR), Emotional detachment (ED), Not caring (NC), Antidepressant as cause (AC)) scores with Workand Social Adjustment Scale (WSAS)/WSAS sub-item scores and PHQ-9/PHQ-9 sub-item scores	—

Secondary

Measure	Time frame
Secondary Endpoint: - Relationship between patient background factors and with/without gap between the degree of subjective EB symptoms and ODQ scores Exploratory Endpoint: - Contribution of ODQ subdomains to WSAS and PHQ-9 after adjusting for interrelationships among WSAS, PHQ-9 and ODQ - Relationship between expressions used by patients and MDD -related characteristics (ODQ, PHQ-9 and subjective EB scores)	—

Measure

Time frame

Secondary Endpoint: - Relationship between patient background factors and with/without gap between the degree of subjective EB symptoms and ODQ scores Exploratory Endpoint: - Contribution of ODQ subdomains to WSAS and PHQ-9 after adjusting for interrelationships among WSAS, PHQ-9 and ODQ - Relationship between expressions used by patients and MDD -related characteristics (ODQ, PHQ-9 and subjective EB scores)

—

Countries

Japan

Contacts

Public ContactFumie Tokuda

Takeda Pharmaceutical Company Limited. Japan Medical Office

fumie.tokuda@takeda.com03-3242-1256

Outcome results